pI: 6.4014 |
Length (AA): 356 |
MW (Da): 40197 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128330)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_37040 | ATP:guanido phosphotransferase, C-terminal catalytic domain containing protein |
Brugia malayi | Bm1_23610 | arginine kinase |
Caenorhabditis elegans | CELE_W10C8.5 | Protein W10C8.5 |
Caenorhabditis elegans | CELE_F32B5.1 | Protein F32B5.1 |
Caenorhabditis elegans | CELE_F46H5.3 | Protein F46H5.3, isoform B |
Caenorhabditis elegans | CELE_F44G3.2 | Protein F44G3.2 |
Caenorhabditis elegans | CELE_ZC434.8 | Protein ZC434.8 |
Chlamydia trachomatis | CT_675 | arginine kinase |
Drosophila melanogaster | Dmel_CG32031 | Arginine kinase |
Homo sapiens | ENSG00000104879 | creatine kinase, muscle |
Homo sapiens | ENSG00000166165 | creatine kinase, brain |
Loa Loa (eye worm) | LOAG_10519 | arginine kinase |
Loa Loa (eye worm) | LOAG_13628 | hypothetical protein |
Loa Loa (eye worm) | LOAG_07634 | ATP:guanido phosphotransferase |
Mus musculus | ENSMUSG00000001270 | creatine kinase, brain |
Mus musculus | ENSMUSG00000030399 | creatine kinase, muscle |
Onchocerca volvulus | OVOC4467 |
|
Onchocerca volvulus | OVOC2321 |
|
Schistosoma japonicum | Sjp_0200590 | ko:K00933 creatine kinase [EC2.7.3.2], putative |
Schistosoma japonicum | Sjp_0124500 | ATP:guanidino kinase SMC74, putative |
Schistosoma mansoni | Smp_194770 | ATP:guanidino kinase (Smc74) |
Schmidtea mediterranea | mk4.004791.03 | |
Schmidtea mediterranea | mk4.018687.00 | |
Schmidtea mediterranea | mk4.002159.01 | |
Schmidtea mediterranea | mk4.008532.00 | |
Schmidtea mediterranea | mk4.001156.04 | |
Schmidtea mediterranea | mk4.000513.00 | |
Schmidtea mediterranea | mk4.007131.02 | |
Schmidtea mediterranea | mk4.007502.01 | |
Trypanosoma brucei gambiense | Tbg972.9.3300 | arginine kinase |
Trypanosoma brucei gambiense | Tbg972.9.3260 | arginine kinase |
Trypanosoma brucei gambiense | Tbg972.9.3280 | arginine kinase |
Trypanosoma brucei gambiense | Tbg972.9.3250 | arginine kinase |
Trypanosoma brucei | Tb927.9.6210 | arginine kinase |
Trypanosoma brucei | Tb927.9.6250 | arginine kinase |
Trypanosoma brucei | Tb927.9.6290 | arginine kinase |
Trypanosoma congolense | TcIL3000_0_36630 | arginine kinase |
Trypanosoma congolense | TcIL3000_9_2150 | arginine kinase |
Trypanosoma cruzi | TcCLB.507241.30 | arginine kinase |
Toxoplasma gondii | TGME49_231610 | ATP:guanido phosphotransferase, C-terminal catalytic domain-containing protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.160.4560 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.4560 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.4560 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.160.4560 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_231610 | Toxoplasma gondii | Probably non-essential | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.2
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Trypanosoma cruzi | arginine kinase | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
Tb927.9.6290 | cloned gene | BRENDA | A gene with this EC number or name or sequence has been cloned from Trypanosoma brucei ( 1 ) |
11 literature references were collected for this gene.